Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Bicycle Therapeutics Plc ADR (NQ: BCYC)
15.65   +0.35 (+2.26%)
Official Closing Price  /  Updated: 7:58 PM EDT, Jul 2, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 1,213,500
Open 15.42
Bid (Size) 15.01 (1)
Ask (Size) 16.99 (1)
Prev. Close 15.30
Today's Range 15.20 - 16.15
52wk Range 6.240 - 19.79
Shares Outstanding N/A
Dividend Yield N/A
Performance
YTD
+59.32%
+59.32%
1 Month
-9.72%
-9.72%
3 Month
+10.57%
+10.57%
6 Month
+50.94%
+50.94%
1 Year
+73.84%
+73.84%
Top News
More News
Bicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today... Read More
from Business Wire News Releases
Oxurion NV Business Update - Q1 2020
from GlobeNewswire News Releases
More News
Read More
Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at AACR Virtual Annual Meeting II
from Business Wire News Releases
Bicycle Therapeutics to Present at Upcoming Investor Conferences
from Business Wire News Releases
Bicycle Therapeutics to Present New Translational Research for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at the AACR Virtual Annual Meeting II
from Business Wire News Releases
Bicycle Therapeutics to Present Trials in Progress Poster for BT5528 at the 2020 American Society of Clinical Oncology Virtual Meeting
from Business Wire News Releases
Bicycle Therapeutics Announces Publication of BT5528 Mechanism of Action in AACR Journal Molecular Cancer Therapeutics
from Business Wire News Releases
Bicycle Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
from Business Wire News Releases
Bicycle Therapeutics to Present at the Bank of America 2020 Health Care Conference
from Business Wire News Releases
Oxurion NV Business Update – FY 2019
from GlobeNewswire News Releases
Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.